ADC deal­mak­ing is red hot. Is it sus­tain­able?

The fren­zied deal­mak­ing for an­ti­body-drug con­ju­gates is far from over.

In the past 10 days, there’s been a slew of ADC deals. Gen­mab made its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.